Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis

A re-evaluation of previously published data of a placebo-controlled randomized study

L. Allegra, F. Blasi, B. De Bernardi, R. Cosentini, P. Tarsia

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The study was designed to extend retrospectively the analysis of a previously reported study on chronic bronchitis patients with acute exacerbations treated with amoxicillin-clavulanic acid or matched placebo. We retrospectively re-clustered patients on the basis of severity of baseline lung function: Cluster 1 (104 patients) mean screening FEV 1 32.67±6.83 (SD); Cluster 2 (109 patients) mean screening FEV 1 54.12±5.56; Cluster 3 (122 patients) mean screening FEV 1 71.54±5.51. The success rate in the antibiotic group was significantly greater compared to the placebo group (P2 test). The differences in final FEV 1 values in the treatment group and placebo group were significantly different (P 1 values showed an improvement following antibiotic treatment and worsening after placebo (P1 values was not significant for both treatment groups. Our patients with severe functional impairment and higher number of exacerbations per year are those who derive the greatest benefit from antibiotic treatment.

Original languageEnglish
Pages (from-to)149-155
Number of pages7
JournalPulmonary Pharmacology and Therapeutics
Volume14
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Chronic Bronchitis
Acute Disease
Screening
Placebos
Anti-Bacterial Agents
Amoxicillin-Potassium Clavulanate Combination
Therapeutics
Lung

Keywords

  • Antibiotics
  • COPD
  • Exacerbations
  • Lung function

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Cite this

@article{b693178a15184c0ca092e375581663e6,
title = "Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: A re-evaluation of previously published data of a placebo-controlled randomized study",
abstract = "The study was designed to extend retrospectively the analysis of a previously reported study on chronic bronchitis patients with acute exacerbations treated with amoxicillin-clavulanic acid or matched placebo. We retrospectively re-clustered patients on the basis of severity of baseline lung function: Cluster 1 (104 patients) mean screening FEV 1 32.67±6.83 (SD); Cluster 2 (109 patients) mean screening FEV 1 54.12±5.56; Cluster 3 (122 patients) mean screening FEV 1 71.54±5.51. The success rate in the antibiotic group was significantly greater compared to the placebo group (P2 test). The differences in final FEV 1 values in the treatment group and placebo group were significantly different (P 1 values showed an improvement following antibiotic treatment and worsening after placebo (P1 values was not significant for both treatment groups. Our patients with severe functional impairment and higher number of exacerbations per year are those who derive the greatest benefit from antibiotic treatment.",
keywords = "Antibiotics, COPD, Exacerbations, Lung function",
author = "L. Allegra and F. Blasi and {De Bernardi}, B. and R. Cosentini and P. Tarsia",
year = "2001",
doi = "10.1006/pupt.2001.0289",
language = "English",
volume = "14",
pages = "149--155",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press",
number = "2",

}

TY - JOUR

T1 - Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis

T2 - A re-evaluation of previously published data of a placebo-controlled randomized study

AU - Allegra, L.

AU - Blasi, F.

AU - De Bernardi, B.

AU - Cosentini, R.

AU - Tarsia, P.

PY - 2001

Y1 - 2001

N2 - The study was designed to extend retrospectively the analysis of a previously reported study on chronic bronchitis patients with acute exacerbations treated with amoxicillin-clavulanic acid or matched placebo. We retrospectively re-clustered patients on the basis of severity of baseline lung function: Cluster 1 (104 patients) mean screening FEV 1 32.67±6.83 (SD); Cluster 2 (109 patients) mean screening FEV 1 54.12±5.56; Cluster 3 (122 patients) mean screening FEV 1 71.54±5.51. The success rate in the antibiotic group was significantly greater compared to the placebo group (P2 test). The differences in final FEV 1 values in the treatment group and placebo group were significantly different (P 1 values showed an improvement following antibiotic treatment and worsening after placebo (P1 values was not significant for both treatment groups. Our patients with severe functional impairment and higher number of exacerbations per year are those who derive the greatest benefit from antibiotic treatment.

AB - The study was designed to extend retrospectively the analysis of a previously reported study on chronic bronchitis patients with acute exacerbations treated with amoxicillin-clavulanic acid or matched placebo. We retrospectively re-clustered patients on the basis of severity of baseline lung function: Cluster 1 (104 patients) mean screening FEV 1 32.67±6.83 (SD); Cluster 2 (109 patients) mean screening FEV 1 54.12±5.56; Cluster 3 (122 patients) mean screening FEV 1 71.54±5.51. The success rate in the antibiotic group was significantly greater compared to the placebo group (P2 test). The differences in final FEV 1 values in the treatment group and placebo group were significantly different (P 1 values showed an improvement following antibiotic treatment and worsening after placebo (P1 values was not significant for both treatment groups. Our patients with severe functional impairment and higher number of exacerbations per year are those who derive the greatest benefit from antibiotic treatment.

KW - Antibiotics

KW - COPD

KW - Exacerbations

KW - Lung function

UR - http://www.scopus.com/inward/record.url?scp=0034968423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034968423&partnerID=8YFLogxK

U2 - 10.1006/pupt.2001.0289

DO - 10.1006/pupt.2001.0289

M3 - Article

VL - 14

SP - 149

EP - 155

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 2

ER -